Key Details
Annual ROE
-98.61%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Mar 10, 2023Recent annual earnings:
Mar 10, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 23, 2020Analyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with SRRA included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Sierra Oncology doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Sierra Oncology?
- What is the ticker symbol for Sierra Oncology?
- Does Sierra Oncology pay dividends?
- What sector is Sierra Oncology in?
- What industry is Sierra Oncology in?
- What country is Sierra Oncology based in?
- When did Sierra Oncology go public?
- Is Sierra Oncology in the S&P 500?
- Is Sierra Oncology in the NASDAQ 100?
- Is Sierra Oncology in the Dow Jones?
- When was Sierra Oncology's last earnings report?
- When does Sierra Oncology report earnings?
What is the primary business of Sierra Oncology?
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.
What is the ticker symbol for Sierra Oncology?
The ticker symbol for Sierra Oncology is NASDAQ:SRRA
Does Sierra Oncology pay dividends?
No, Sierra Oncology does not pay dividends
What sector is Sierra Oncology in?
Sierra Oncology is in the Healthcare sector
What industry is Sierra Oncology in?
Sierra Oncology is in the Biotechnology industry
What country is Sierra Oncology based in?
Sierra Oncology is headquartered in United States
When did Sierra Oncology go public?
Sierra Oncology's initial public offering (IPO) was on 16 July 2015
Is Sierra Oncology in the S&P 500?
No, Sierra Oncology is not included in the S&P 500 index
Is Sierra Oncology in the NASDAQ 100?
No, Sierra Oncology is not included in the NASDAQ 100 index
Is Sierra Oncology in the Dow Jones?
No, Sierra Oncology is not included in the Dow Jones index
When was Sierra Oncology's last earnings report?
Sierra Oncology's most recent earnings report was on 10 March 2023
When does Sierra Oncology report earnings?
The date for Sierra Oncology's next earnings report has not been announced yet